Results 81 to 90 of about 240,442 (260)

microRNA‐7‐5p and α‐Synuclein SAA Predict Parkinson's Disease Phenoconversion

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Corroborate blood neuron‐derived extracellular vesicle (NDEV) alpha‐synuclein (αSyn), the CSF αSyn seed amplification assay (αSyn‐SAA), and blood microRNA‐7‐5p (miR‐7‐5p) as markers for Parkinson's disease (PD) phenoconversion and determine if combining these markers would help select subjects who would be more likely to phenoconvert.
Shayan Zadegan   +4 more
wiley   +1 more source

Resurgence of Malaria in Protected and Rural Areas After Successful Control Program in a Brazilian Amazon Municipality

open access: yesGeoHealth
Malaria eradication requires reducing transmission in endemic areas and maintaining these reductions in areas where elimination has been achieved. In Altamira, a municipality in the Xingu Basin of the Brazilian Amazon, a malaria control program was ...
E. B. Skinner   +5 more
doaj   +1 more source

A Two‐Stage Plasma Biomarker Algorithm Reduces Amyloid PET Use and the p‐Tau217 Gray Zone

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma p‐Tau217 leaves 30%–50% of patients in an indeterminate “gray zone” often requiring Aβ‐PET. We developed GRAD (Gatekeeper‐Reflex for Alzheimer's Disease), a two‐stage Aβ‐positivity prediction model to improve classification while reserving Aβ‐PET for residual uncertainty.
Harthik Parankusham   +7 more
wiley   +1 more source

Hybrid taguchi-harmony search approach for shape optimization

open access: yes, 2010
Harmony search algorithms have recently gained a lot of attention from the optimization research community. In this chater, a new optimization approach based on harmony search algorithm and Taguchi's method is presented to solve shape optimization ...

core   +1 more source

Artificial Intelligence in Systemic Sclerosis: Clinical Applications, Challenges, and Future Directions

open access: yesArthritis Care &Research, EarlyView.
Systemic sclerosis (SSc) is a rare autoimmune disease defined by immune dysregulation, vasculopathy, and progressive fibrosis of the skin and internal organs. Despite advances in care, major complications such as interstitial lung disease (ILD) and myocardial involvement remain the leading causes of morbidity and mortality.
Cristiana Sieiro Santos   +2 more
wiley   +1 more source

A functional model of role expectations in child-parent relationships

open access: yesТеоретическая и экспериментальная психология
Background. The problem of parents and children remains relevant at all times. Professionals working with families in counseling practice every day face with the need to find professional answers to the questions posed to them.
Julia V. Budagova
doaj   +1 more source

Immunosuppressive Drug Use in Limited Systemic Sclerosis: An International Survey

open access: yesArthritis Care &Research, EarlyView.
Objective Current guidelines recommend immunosuppressive treatment for diffuse cutaneous systemic sclerosis but are less clear on their use in limited cutaneous systemic sclerosis (lcSSc) in the absence of internal organ complications. We conducted an international survey to understand current immunosuppressive drug prescribing patterns in lcSSc ...
Sabrina Hoa   +3 more
wiley   +1 more source

Fauntleroy at New Harmony

open access: yes, 2007
New Harmony Sketches Attributed to LeSueur, ca. 1826-1837: Fauntleroy at New Harmony.
LeSueur, Charles Alexandre, 1778-1846
core  

From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis

open access: yesArthritis Care &Research, EarlyView.
Spondyloarthritis (SpA) is a group of chronic inflammatory diseases encompassing axial and peripheral forms, with up to 20% of patients developing symptoms before age 16. Despite this substantial pediatric burden, treatment options for juvenile‐onset SpA (JSpA), particularly those with axial disease (axJSpA), remain limited.
Pamela F. Weiss   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy